Testing effectiveness (Phase 2)Study completedNCT04983888What this trial is testingObinutuzumab in Primary FSGSWho this might be right forPrimary Focal Segmental Glomerulosclerosis Mayo Clinic 20
Testing effectiveness (Phase 2)Study completedNCT02000440What this trial is testingA Phase II, Repeat Dose, Proof of Mechanism Study of Losmapimod to Reduce Proteinuria in Patients With Focal Segmental Glomerulosclerosis (FSGS)Who this might be right forGlomerulosclerosis, Focal Segmental GlaxoSmithKline 17
Large-scale testing (Phase 3)Looking for participantsNCT07220083What this trial is testingFind Out if BI 764198 Helps Adults and Adolescents With a Kidney Condition Called Focal Segmental Glomerulosclerosis (FSGS)Who this might be right forFocal Segmental Glomerulosclerosis Boehringer Ingelheim 286
Not applicableLooking for participantsNCT02235857What this trial is testingPost Approval Study of Liposorber LA-15 System for the Treatment of Focal Segmental Glomerulosclerosis in ChildrenWho this might be right forFocal Segmental Glomerulosclerosis Kaneka Medical America LLC 35
Testing effectiveness (Phase 2)Study completedNCT03649152What this trial is testingSafety and Effectiveness of Propagermanium in Focal Segmental Glomerulosclerosis Participants Receiving IrbesartanWho this might be right forFocal Segmental Glomerulosclerosis Dimerix Bioscience Pty Ltd 8
Testing effectiveness (Phase 2)Study completedNCT01665391What this trial is testingFresolimumab in Patients With Steroid-Resistant Primary Focal Segmental Glomerulosclerosis (FSGS)Who this might be right forPrimary Focal Segmental Glomerulosclerosis Genzyme, a Sanofi Company 36
Testing effectiveness (Phase 2)WithdrawnNCT00550342What this trial is testingRituximab Treatment of Focal Segmental GlomerulosclerosisWho this might be right forFocal Segmental Glomerulosclerosis (FSGS) National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Post-approval studies (Phase 4)Study completedNCT02633046What this trial is testingActhar for Treatment-Resistant or Treatment-Intolerant ProteinuriaWho this might be right forIdiopathic Focal Segmental Glomerulosclerosis Mallinckrodt ARD LLC 63
Testing effectiveness (Phase 2)Ended earlyNCT05441826What this trial is testingEfficacy and Safety of VB119 in Subjects With Minimal Change Disease (MCD) and Focal Segmental Glomerulosclerosis (FSGS)Who this might be right forMinimal Change DiseaseFocal Segmental Glomerulosclerosis Tenet Medicines 1
Not applicableLooking for participantsNCT06065852What this trial is testingNational Registry of Rare Kidney DiseasesWho this might be right forAdenine Phosphoribosyltransferase DeficiencyAH AmyloidosisAHL Amyloidosis+81 more UK Kidney Association 35,000
Early research (Phase 1)Study completedNCT05314231What this trial is testingSafety and Pharmacokinetic Study of Subcutaneous ALXN1720 in Participants With ProteinuriaWho this might be right forProteinuria Alexion Pharmaceuticals, Inc. 13
Not applicableStudy completedNCT03126201What this trial is testingPredictors of Disease Progression in Primary Focal Segmental GlomerulosclerosisWho this might be right forGlomerulonephritisFocal Segmental Glomerulosclerosis Istanbul University 86
Testing effectiveness (Phase 2)Study completedNCT00814255What this trial is testingNovel Therapies for Resistant FSGS (FONTII): Phase II Clinical TrialWho this might be right forFocal Segmental Glomerulosclerosis NYU Langone Health 32
Early research (Phase 1)Ended earlyNCT00816478What this trial is testingEffect of Oral Galactose on Focal Segmental Glomerulosclerosis (FSGS) Permeability FactorWho this might be right forFocal Segmental Glomerulosclerosis Northwell Health 15
Testing effectiveness (Phase 2)Study completedNCT01613118What this trial is testingRandomized, Double-Blind, Safety and Efficacy Study of RE-021 (Sparsentan) in Focal Segmental GlomerulosclerosisWho this might be right forFocal Segmental Glomerulosclerosis Travere Therapeutics, Inc. 109
Testing effectiveness (Phase 2)Looking for participantsNCT06500702What this trial is testingEvaluate the Efficacy and Safety of Frexalimab, Brivekimig, or Rilzabrutinib in Participants Aged 16 to 75 Years With Primary Focal Segmental Glomerulosclerosis or Minimal Change DiseaseWho this might be right forFocal Segmental GlomerulosclerosisGlomerulonephritis Minimal Lesion Sanofi 84
Not applicableStudy completedNCT04369183What this trial is testingRituximab for Refractory or Relapsed Focal Segmental Glomerulosclerosis or Minimal Change DiseaseWho this might be right forFocal Segmental GlomerulosclerosisMinimal Change Disease Istanbul University 25
Early research (Phase 1)WithdrawnNCT00816504What this trial is testingEffect of Galactose on Permeblity Factor in Patients With FSGS and CKD Stage 5Who this might be right forFocal Segmental Glomerulosclerosis Northwell Health
Testing effectiveness (Phase 2)Study completedNCT01573533What this trial is testingA Pilot Study to Assess the Efficacy of Rituximab Therapy in Treatment Resistant FSGSWho this might be right forPrimary Focal Segmental Glomerulosclerosis Mayo Clinic 9
Not applicableLooking for participantsNCT04065438What this trial is testingPost Approval Study for Treatment of Drug-resistant Adult and Pediatric Primary FSGS Using the LIPOSORBER® LA-15 SystemWho this might be right forFocal Segmental Glomerulosclerosis Kaneka Medical America LLC 35